Stem cells and beta cell replacement therapy: a prospective health technology assessment study

Wallner, Klemens; Pedroza, Rene G.; Awotwe, Isaac; Piret, James M.; Senior, Peter A.; Shapiro, A. M. James; McCabe, Christopher

doi:10.1186/s12902-018-0233-7

BMC Endocrine Disorders

Table 3 Results for different scenarios using suspension cell culture (means per patient)

From: Stem cells and beta cell replacement therapy: a prospective health technology assessment study

Scenario						Cost		Benefit		ICER	EVPI		Maximum Partial EVPI Dose Costs
Index	Production mode	Supply per facility	COGd factor	Regulatory factor	Variation (RSD^a)	Strategy	Difference	Strategy	Difference		WTP per QALY
Index	Production mode	Supply per facility	COGd factor	Regulatory factor	Variation (RSD^a)	Strategy	Difference	Strategy	Difference		$50,000	$100,000
Scenarios with 3% discount rate
Comp1	(Comparator 3%)					74,230		11.12
Sus1	Local	50	4	1.2	22.5%	480,575	406,346	13.85	2.73	148,790	56	12,126	59,158
Sus2	Local	50	4	1.2	50.0%	479,911	405,680	13.85	2.73	148,546	1541	35,232	92,836
Sus3	Local	50	4	1.8	22.5%	654,137	579,906	13.85	2.73	212,342	4	2464	88,524
Sus4	Local	50	4	1.8	50.0%	651,401	577,171	13.85	2.73	211,340	450	16,335	141,768
Sus5	Scale out local	50	3	1.2	22.5%	393,796	319,566	13.85	2.73	117,014	305	28,627	47,474
Sus6	Scale out local	50	3	1.2	50.0%	393,094	318,864	13.85	2.73	116,757	3215	53,937	76,931
Sus7	Scale out local	50	3	1.8	22.5%	523,705	449,475	13.85	2.73	164,582	33	8084	66,874
Sus8	Scale out local	50	3	1.8	50.0%	521,437	447,207	13.85	2.73	163,752	1084	28,588	113,389
Sus9	Scale out local	50	8	1.8	22.5%	1,172,878	1,098,648	13.85	2.73	402,287	0	50	169,848
Sus10	Scale out local	50	8	1.8	50.0%	1,163,974	1,089,744	13.85	2.73	399,026	35	2719	295,702
Sus11	Large scale	500	4	1.2	22.5%	421,724	347,494	13.85	2.73	127,240	590	28,370	59,316
Sus12	Large scale	500	4	1.2	50.0%	420,338	346,108	13.85	2.73	126,733	3399	51,260	83,398
Sus13	Large scale	500	4	1.8	22.5%	565,342	491,112	13.85	2.73	179,828	116	9785	86,421
Sus14	Large scale	500	4	1.8	50.0%	562,360	488,130	13.85	2.73	178,736	1294	27,942	124,381
Sus15	Scale out large	500	3	1.2	22.5%	349,649	275,419	13.85	2.73	100,848	1666	43,136	47,205
Sus16	Scale out large	500	3	1.2	50.0%	349,048	274,819	13.85	2.73	100,629	6192	64,312	64,826
Sus17	Scale out large	500	3	1.8	22.5%	457,207	382,977	13.85	2.73	140,232	384	21,505	67,653
Sus18	Scale out large	500	3	1.8	50.0%	455,948	381,718	13.85	2.73	139,772	2669	43,714	101,004
Scenarios with 0% discount rate
Comp2	(Comparator 0%)					113,175		16.09
Sus19	Local	50	4	1.2	22.5%	514,909	401,734	20.60	4.51	89,173	4389	40,830	59,131
Sus20	Scale out large	500	3	1.2	22.5%	383,981	270,808	20.60	4.51	60,111	26,451	7684	47,205
Scenarios with 5% discount rate
Comp3	(Comparator 5%)					56,558		9.09
Sus21	Local	50	4	1.2	22.5%	468,087	409,529	11.18	2.09	196,160	1	2042	59,162
Sus22	Scale out large	500	3	1.2	22.5%	337,161	278,602	11.18	2.09	133,447	172	16,410	47,207

All scenarios used the base case assumptions with the described structural deviations. Cost measure is Canadian dollar (2016). Benefit measure is QALY. All result numbers are rounded and including sampling variation
^aRelative standard deviation (RSD; i.e. SD as percentage of the mean) that was assumed for the two factors

Back to article page

ISSN: 1472-6823

Contact us

General enquiries: journalsubmissions@springernature.com